Feasibility of Semaglutide in Advanced Lung Disease
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 18 Years to 80 Years; excludes diabetes; BMI ≥30 required; conditions: Obesity; Interstitial Lung Disease; Chronic Obstructive Pulmonary Disease; Sarcoidosis, Pulmonary
- Interventions
- Semaglutide Pen Injector
- Conditions
- Obesity; Interstitial Lung Disease; Chronic Obstructive Pulmonary Disease; Sarcoidosis, Pulmonary; Pulmonary Hypertension
- Phase and size
- Phase 1, Phase 2 · 8 participants
- Dates
- Start 2024-01-29
Primary completion 2027-12-28 - Sponsor
- University of Pennsylvania (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Tolerability12 weeks
02Eligibility
Who can take part
Inclusion Criteria: * Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension * Age \> 18 * BMI \> 30 kg/m2 * Requires supplemental oxygen on exertion * Stable treatment regimen X 90 days * Use of disease-modifying therapy Exclusion Criteria: * Diabetes * Pregnant or Breastfeeding * Recent weight loss * Recent or chronic GI complaints * History of gastroparesis * History of scleroderma * Hospitalized at time of evaluation * Use of weight loss medication in last 90 days * Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2) * Uncontrolled thyroid disease * History of acute/chronic pancreatitis * Prior suicide attempt * Suicidal ideation in last 90 days * Presence of a pacemaker or defibrillator
03Change log
Registry changes
No changes recorded since the trial was added.